Regulatory risk Recent data privacy regulatory actions in Italy resulting in a multi-million euro penalty highlight heightened compliance risks for IQVIA and its life sciences clients. This presents an opportunity to position enhanced data governance, privacy protection services, and compliant data processing workflows as essential value-adds for customers navigating global regulatory environments.

Clinical tech expansion IQVIA’s recent launches and partnerships around Life Science Models and Explorer tools, as well as expanding Veeva Systems integration for CTMS, eTMF and Site Connect, indicate a strong push toward advanced analytics and automated clinical operations. This creates sales opportunities for customers seeking improved trial outcomes, faster study startup, and integrated clinical trial management.

Global execution scale With a large global footprint and extensive data resources, IQVIA Canada can be a gateway for multinationals to standardize their clinical development and market access analytics across North America. Opportunities exist to offer standardized analytics platforms, privacy-preserving data sharing, and regionally tailored insights to global clients.

Privacy first value IQVIA emphasizes patient privacy and privacy-enhancing technologies, which can be leveraged to reassure health authorities and payers. This opens conversations with life sciences firms seeking compliant data analytics, real-world evidence generation, and de-identified data products to support regulatory submissions and payer negotiations.

Small to mid-market focus IQVIA Canada operates with 201-500 employees and revenue in the lower-mids range, suggesting a potential affinity for scalable, modular solutions and managed services. Target opportunities include modular analytics, cloud-based data integration, and affordable entry-point offerings that can scale as customers grow.